# Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines

> **NCT00838370** · PHASE1 · COMPLETED · sponsor: **The Netherlands Cancer Institute** · enrollment: 22 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Capecitabine, 5-fluorouracil

## Key facts

- **NCT ID:** NCT00838370
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838370, "Pharmacogenomic and Pharmacokinetic Safety and Cost-saving Analysis in Patients Treated With Fluoropyrimidines". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00838370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*